XML 33 R26.htm IDEA: XBRL DOCUMENT v3.19.3
Significant Accounting Policies - Additional Information (Detail)
9 Months Ended 12 Months Ended
Sep. 30, 2019
USD ($)
Segment
Customer
Sep. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2012
USD ($)
Significant Accounting Policies [Line Items]        
Trade receivables, credit period 30 days      
Number of operating segments | Segment 1      
Minimum        
Significant Accounting Policies [Line Items]        
Trade receivables, credit period 30 days      
Maximum        
Significant Accounting Policies [Line Items]        
Trade receivables, credit period 60 days      
Embedded Derivative Financial Instruments | BioPharma Debt        
Significant Accounting Policies [Line Items]        
Maximum repayment of future revenue and receivables       $ 150,000,000.0
Fair value of embedded derivative liability $ 0   $ 0  
Gain (loss) on change in fair value of derivative liabilities $ 0 $ 0    
Embedded Derivative Financial Instruments | BioPharma Debt | Minimum        
Significant Accounting Policies [Line Items]        
Derivative liability fair value assumption, coupon rate 6.40%   5.40%  
Derivative liability fair value assumptions, market yields 5.40%   6.70%  
Embedded Derivative Financial Instruments | BioPharma Debt | Maximum        
Significant Accounting Policies [Line Items]        
Derivative liability fair value assumption, coupon rate 11.50%   10.80%  
Derivative liability fair value assumptions, market yields 18.20%   15.80%  
Embedded Derivative Financial Instruments | BioPharma Debt | Measurement Input, Expected Term | Minimum        
Significant Accounting Policies [Line Items]        
Derivative liability fair value assumptions, term 9 months 18 days   1 year 3 months 18 days  
Embedded Derivative Financial Instruments | BioPharma Debt | Measurement Input, Expected Term | Maximum        
Significant Accounting Policies [Line Items]        
Derivative liability fair value assumptions, term 7 years 7 months 6 days   4 years  
Long-term debt from royalty-bearing instrument        
Significant Accounting Policies [Line Items]        
Long-term debt, discount $ 0   $ 0  
Gross Product Sales | Customer Concentration Risk        
Significant Accounting Policies [Line Items]        
Number of customers | Customer 3      
Customer A | Gross Product Sales | Customer Concentration Risk        
Significant Accounting Policies [Line Items]        
Concentration risk percentage 25.00% 26.00%    
Customer A | Accounts Receivable | Customer Concentration Risk        
Significant Accounting Policies [Line Items]        
Concentration risk percentage 42.00% 37.00%    
Customer B | Gross Product Sales | Customer Concentration Risk        
Significant Accounting Policies [Line Items]        
Concentration risk percentage 36.00% 31.00%    
Customer B | Accounts Receivable | Customer Concentration Risk        
Significant Accounting Policies [Line Items]        
Concentration risk percentage 23.00% 33.00%    
Customer C | Gross Product Sales | Customer Concentration Risk        
Significant Accounting Policies [Line Items]        
Concentration risk percentage 29.00% 31.00%    
Customer C | Accounts Receivable | Customer Concentration Risk        
Significant Accounting Policies [Line Items]        
Concentration risk percentage 28.00% 17.00%